Список литературы

Поставить закладку

Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361: 1676–1687
Campistol J.M., Arias M., Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27-45.
Gavriilaki E., Anagnostopoulos A., Mastellos D.C. Complement in thrombotic microangoipathies: unreveling Ariadneʾs thread into labyrinth of complement therapeutics. Front. Immunol. 2019;10:337doi:10.3389/fimmu.2019.00337
Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr. 2014;61(1):335-356.
Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010; 21: 2180-2187
Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–562
Yoshida Y, Kato H, IkedaY, Nangaku M. Pathogenesis of atypical haemolytic uraemic syndrome. J Atheroscler Thromb 2019;26:99-110. http://doi.org/10.5551/jat.RV17026
Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40:422-430 doi:10.1055/s-0034- 1375296
Jozsi M, Licht C, Strobel S et al. Factor F autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-1514
Noris M., Mescia F., Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation // Nat Rev Nephrol. 2012; 8 (11): 622–633.
Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013; 24(6):496-502. http://dx.doi.org/10.1016/j.ejim.2013.05.009
Riedl M, Fakhouri F, Le Quintrec M et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014;40:444-464.
Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet 2017;390:681-696 doi:10.1016/S0140-6736(17)30062-4
Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies . Blood Rev. 2014;28(2):67-74.
Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60 doi:10.1186/1750-1172-6-60.
Yan K, Desai K, Gullapalli L et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clinical Epidemiology 2020;12:295-305.
Besbas N, Karpman D, Landau, Daniel L.C. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, and related disorders. Europian Paediatric Research Group for HUS. Kidney International 2006;70:423-431.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594
Moake J Thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Best Practice&Research Clinical Haematology 2009;22:567-576.
Goodship TH, Cook HT, Fakhouri F. Fervenza FC, Frémeaux-Bacchi V, Kavanagh D et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusion from a “Kidney Disease: improving Global Outcomes” (KDIGO) controversies conference. Kidney Int.2017;91(3):539-551 doi: 10.1016/j.kint.2016.10.005
Kato H, Nangaku M, Okada H, Kagami S. Controversies of the classification of TMA and the terminology of aHUS. Clinical and Experimental Nephrology https://doi.org/10.1007/ s10157-017-1524-4.
Le Clech A, Simon-Tillaux N, Provot F et al. Atypical and secondary hemolytic uremic syndrome have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95:1443-1452; https://doi.org/10.1016/j.kint2019.01.023
Praga M, Rodriguez de Cordoba S. Secondary atypical hemolytic uremic syndrome in the era of complement blockade. Kidney Int. 2019; 95:1298-1300; https://doi.org/10.1016/j/kint2019.01.043
Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the кidney. Clin J Am Soc Nephrol 2018;13:300–317,. doi: https://doi.org/10.2215/CJN.00620117
Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clinical Kidney Journal, 2019; 12(3): 333–337 doi: 10.1093/ckj/sfz040
Sallée M, Ismail K, Fakhouri F et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol. 2013;14(3):1–6.
Hofer J, Rosales A, Fisher C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Pediatric Nephrol 2014; 2, article 97:1-16.
Swisher KK, Doan JT, Vesely SK. et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92:936-943
Noris M., Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome Nat Rev Nephrol. 2014; 10(3): 174-180
Sallee M, Daniel L, Piercecchi M et al. Myocardial infarction is a complication of factor H associated atypical HUS. Nephrol Dial Transplant 2010; 25: 2028–2032.
Jokiranta S. HUS and atypical HUS Blood. 2017; 21 (129): 2847–2856.
Gulleroglu K, Fidan K, Hançer VS et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013; 28(5): 827-30. doi: 10.1007/s00467-013-2416-9.
Кучиева А.М, Козловская Н.Л., Демьянова К.А., Добросмыслов И.А. Рецидивирующий атипичный гемолитико-уремический синдром, манифестировавший поражением поджелудочной железы. Нефрология и диализ 2013;15 (3): 236-239.
Коротчаева Ю.В., Козловская Н.Л., Бондаренко Т.В., Веселов Г.А. Особенности течения и лечения «акушерского» гемолитико-уремического синдрома. Нефрология, 2015; 19 (2):76-81.
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A et al. An international consensus approach to the management of the atypical hemolytic uremic syndrome in chidren. Pediatr Nephrol 2016;31(1):15-39. doi:10.1007/s00467-015-3076-8.
Scully M, Goodship T. How I Treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Br J Haematol 2014;164(6):759-766/ doi:10.1111/bjh.12718.
Azoulay E., Knoeble P, Garnacho-Montero J. et al. Expert Statements on the Standard of Care in Critically Ill Adult Patients with Atypical Hemolytic Uremic Syndrome. // Chest 2017; 152(2):424-434.
Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thrombosis Journal 2016;14 (suppl 1):19. Doi:10.1186/s12959-016-0114-0
Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO et al. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci 2016; 31:1516-1528. http://dx.doi.org/10.3346/jkms.2016.31.10.1516
Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH.2009;148:37-47
Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R et al. Clinical guides for atypical haemolytic uraemic syndrome in Japan. Clin Exp Nephrol 2016. Doi10/1007/s10157-016-1276-6
Go RS, Winters JL, Leug N, Murray DL, Willrich MA, Abraham RS et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group // Mayo Clin Proc 2016;91(9) 1189-1211. http://dx.doi.org./10.1016/j.mayocp.2016.05.015
Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616-618.
Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017 Jun;30(3):347-362. doi: 10.1007/s40620-016-0357-7
El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2015;65(1):127-130/
Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L. et al. Pregnancy- associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21:859-867.
Zhang B, Xing C, Yu X, Sun B, Zhao X, Qian J. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 2008; 31:479-483.
Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, et al. Patients with hypertension- associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 2017; 91:1420-1425.
Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease. World J Transplant 2018; 8:122-141.
Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome:case-control study. BMJ 2012; Jul 19;345:e4565. doi: 10.1136/bmj.e4565.
Cataland SR, Wu HM. Atypical haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. // Eur J Intern Med. 2013; 24:486-491.
Scully M., Hunt B.J., Benjamin S, Liesner R, Rose P, Peyvandi F. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. // BJH 2012; 158 (3): 323–335.doi:10.1111/j.1365-2141.2012.09167.x
Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol. 2012;157(4):501-503.
Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010; 5(4):e10208.
Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J 2018; 16:14. doi: 10.1186/s12959-018-0168-2
Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med 2020; 35(1):25-40. DOI: https://doi.org/10.3904/kjim.2019.388
Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 2014;133 Suppl 1: S28-S31.
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859.
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-62.
Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33:508-530. doi: 10.1016/j.semnephrol.2013.08.003
Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014; 123:3733-3738
Noris M, Galbusera M, Gastoldi S, Macor P, Banteria F, Bresin E. et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124:1715-1726
Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018; 94: 408-418 doi: 10.1016/j.kint.2018.02.029
KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl.2012;2:1-138
Campistol JM., Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2015;35(5):421-447. doi: 10.1016/j.nefro.2015.07.005.
De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 2009; 24:1048-1050
Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011; 7(1):23-35. doi: 10.1038/nrneph.2010.155.
Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C et al. International Registry of Recurrent and Familial HUS/TTP.Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006 15;108(4):1267-1279. doi: 10.1182/blood-2005-10-007252
Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange.Seminars in Dialysis 2012;25(2):214-219.DOI:10.1111/j.1525-139X.2011.01035x.
Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand Nephrology (Carlton) 2018;23(6):507-517. doi: 10.1111/nep.13234
Loirat C, Grnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost.2010;36:673-681.
Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int 2016; 90:974-984 doi: 10.1016/j.kint.2016.06.009.
Schwartz J, Padmanabhan A, Aqui N,. Balogun RA, Connelly‐Smith L, Delaney M. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 2016; 31:149-162. https://doi.org/10.1002/jca.21470
Claes KJ, Massart A, Collard L, Weekers L, Goffin E, Pochet JMet al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg 2018; 73:80-89. http://doi.org/10.1080/17843286.2017.1345185
Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth. special issue. J Clin Apher 2013;28(3):145-284
Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher.1998;13(1):16-19
Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8:643-657. doi: 10.1038/nrneph.2012.214
Kise T, Fukuyama S, Uehara M Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol 2020; 30(1):35-38. doi: 10.4103/ ijn.IJN_336_18
Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouviére C, Bérard E, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol. 2014; 29:75–83.
Sincha A, Gulati A, Saini S, Blanc S, Gupta A, Gurjar BS et al. Indian HUS Registry. Prompt plasma exchange and immunosuppressive treatment improves the outcomes of anti- factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int.2014;85(5):1151-1160.
Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle A, Ogawa М et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS Вlood 2015 21;125(21):3253-62. doi: 10.1182/blood-2014-09-600411.
Legendre CM, Licht C, Muus PL, Greenbaum A, Babu S, Bedrosian C et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368:2169–2181. doi:10.1056/ NEJMoa1208981
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87:1061–1073. doi:10.1038/ki.2014.423
Krishnappa V, Gupta M, Shah H, Moftakhar B, Ensley MJ, Vachharajani TJ et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018; 22:178–188. doi:10.1111/1744-9987.12641
Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long- term observational study. Clin Kidney J 2018;12(2):196-205. doi: 10.1093/ckj/sfy035.
Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. KIReports 2019; 4:1568-1576; http://doi.org/10.1016/j.ekir.2019.07.016
Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology 2019; 20:125-137. https://doi.org/10.1186/s12882- 019-1314-1
Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015;66:172- 173
Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DelLoughery TG. When to stop Eculizumab in complement-mediated microangiopathies. Am J Nephrol 2018;48:96-107. Doi:10.1159/000492033
Каабак М.М., Молчанова Е.А., Нестеренко И.В., Пинчук А.В., Прокопенко Е.И., Столяревич Е.С., Сушков А.И., Томилина Н.А., Цыгин А.Н., Эмирова Х.М., Бабенко Н.Н. Резолюция Междисциплинарного совета экспертов. Трансплантация почки у пациентов с атипичным гемолитико-уремическим синдромом: клинические и организационно-методические аспекты ведения пациентов. Нефрология. 2018; 3: 8-14. doi: 10.18565/nephrology.2018.3.8-14
Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(7). pii: E919. doi: 10.3390/jcm8070919
Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ; Global aHUS Registry. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2018 Dec 3;4(3):434-446. doi: 10.1016/j.ekir.2018.11.010
Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73(18):2053-66. doi: 10.1007/s40265-013-0147-7.
Avery RK, Ljungman P. Prophylactic measures in the solid-organ recipient before transplantation. Clin. Infect. Dis. 2001; 33(1):S. 15–21. doi: 10.1086/320899
Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice Guidelines for vaccination of solid organ transplant candidates and recipients. Am. J. Transplant. 2009;9(4):258–262. doi: 10.1111/j.1600-6143.2009.02917.x.
Резолюция Междисциплинарного совета экспертов по профилактике тяжелых инфекций у пациентов с генетическими нарушениями регуляции системы комплемента, получающих терапию экулизумабом. Эпидемиология и вакцинопрофилактика. 2017; 1 (92): 51–55
Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006; 1: 88–99. doi: 10.2215/CJN.00050505
Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol. Dial. Transplant. 2006; 21: 2724–2735. doi: 10.1093/ndt/gfl340
Nava F, Cappelli G, Mori G, Granito M, Magnoni G, Botta C, Solazzo A, Fontana F, Baisi A, Bonucchi D. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant. Proc. 2014; 46: 2263-2268. doi: 10.1016/j.transproceed.2014.07.062
Schwimmer J., Nadasdy T.A., Spitalnik P.F., Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am. J. Kidney Dis. 2003; 41: 471-479. doi: 10.1053/ajkd.2003.50058
Rolla D, Fontana I, Ravetti JL, Marsano L, Bellino D, Panaro L, Ansaldo F, Mathiasen L, Storace G, Trezzi M. De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia. J. Renal. Inj. Prev. 2015; 4(4):135-138. doi: 10.12861/jrip.2015.28
Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J. Nephrol. 2017; 30(1):127-134. doi: 10.1007/s40620-016-0288-3
Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am. J. Transplant. 2012; 12:3337-3354. doi: 10.1111/j.1600-6143.2012. 04252.x
Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014; 98(11): 1205-1212. doi: 10.1097/TP.0000000000000200
Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12:1440-1448
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL et al. Genetic variants in C5 and poor response to eculizumab N Engl J Med 2014;370:632-639
Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017 Aug 7; 12(8):1237- 1247 doi: http://doi.org/10.2215/CJN.00280117
Gupta M, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome. A systematic review. Obstetrics & Gynecology 2020; 135: 46-58 Doi:10.1097/AOG0000000000003554
Grand'Maison S, Lapinsky S. Insights into pregnancy associated and atypical hemolytic uremic syndrome [published correction appears in Obstet Med. 2018 Dec;11(4):198]. Obstet Med. 2018;11(3):137–140. doi:10.1177/1753495X18780099
Коротчаева Ю.В., Козловская Н.Л., Демьянова К.А. и соавт. Генетические аспекты акушерского гемолитико-уремического синдрома. // Клиническая нефрология 2017; №1:12-17
Huerta A., Arjona E., Portoles J. et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018 Feb;93(2):450-459. doi: 10.1016/j.kint.2017.06.022.
Козловская Н.Л., Коротчаева Ю.В., Шифман Е.М., Кудлай Д.А. Акушерский атипичный гемолитико-уремический синдром: виновата беременность или её осложнения? Вопросы гинекологии, акушерства и перинатологии, 2020; том 19 (№4): 81–91 DOI: 10.20953/1726–1678-2020-4-81-91
Кирсанова Т.В., Виноградова М.А., Федорова Т.А. Имитаторы тяжелой преэклампсии и HELLP- синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью Акушерство и гинекология 2016; 12: 5-14 DOI: 10.18565/aig.2016.12.5-14
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705.
Stefanovic V. The Extended Use of Eculizumab in pregnancy and complement activation⁻associated diseases affecting maternal, fetal and neonatal kidneys - the future is now? J Clin Med. 2019;8(3):407. Published 2019 Mar 24. doi:10.3390/jcm8030407
Burlinson CEG, Sirounis D, Wally KR, Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth 2018 Nov; 36:96-107. doi: 10.1016/j.ijoa.2018.04.010.
Nabhan AF, Allam NE, Hamed Abdel-Aziz Salama M. Routes of administration of antibiotic prophylaxis for preventing infection after caesarean section. Cochrane Database Syst Rev. 2016 Jun 17;(6):CD011876. doi: 10.1002/14651858.CD011876.pub2